HER2 Mutation Detection Kit
PCR
Real-time PCR Assays
Product Description

HER2 Mutation Detection Kit

Human epidermal growth factor receptor 2 (HER2), also known as Neu, ErbB-2, CD340 (cluster of differentiation 340) or pl85, is encoded by a proto-oncogene ERBB2 which located at the long arm of human chromosome 17 (17ql2). Activating mutations in the tyrosine kinase domain of HER2 have been described in a subset of lung adenocarcinomas (ADCs) and are mutually exclusive with EGFR/KRAS/ALK driver mutations. HER2 mutations, consisting of in-frame insertions in exon 20, have been identified in approximately 2-4% of non-small cell lung cancer (NSCLC) patients. These insertions cause activation of downstream ZZER2-pathway components such as AKT and MEK.

Studies have shown that NSCLC patients harboring a HER2 exon 20 insertion are sensitive to trastuzumab (marketed as Herceptin) and the irreversible dual EGFR and HER2 TKIs, lapatinib, neratinib, and afatinib. However, the presence of this mutation is associated with primary resistance to the first generation EGFR TKIs, erlotinib and gefitinib. These studies highlighted the importance of screening for HER2 mutations in NSCLC and suggest that ZZER2-positive patients may be responsive to fZEZ?2-targeted therapy.

Intended Use

The AmoyDx® HER2 Mutation Detection Kit is a real-time PCR assay for qualitative detection of 13 mutations in HER2 gene in human genomic DNA extracted from formalin-fixed paraffin-embedded (FFPE) tumor tissue.

The kit is for research use only, and intended to be used by trained professionals in a laboratory environment.

Testing Procedure
Compatible Sample Types:FFPE Samples
Compatible Real-time PCR Instrument
ABI 7500
ABI 7900HT
ABI StepOnePlus
Bio-Rad CFX96
LightCycler 480
Rotor-Gene 6000
Rotor-Gene Q
SLAN-96S
Stratagene Mx3000P™
Other Info.

To order, please contact sales@amoydx.com.

Product Name Type Size (test/kit)  Storage
AmoyDx® HER2 Mutation Detection Kit Bulk 24 -20±5℃

Publications
1. Li, Xuefei, et al. "Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China." Bmc Cancer 16.1 (2016): 828.

Certificate
BACK
Inquiry
Inquiry
* Required information
Manage your account info
Change your password